Kornimate/medical-research-clean huggingface dataset:
long pulse versus short pulse laser dusting for renal stones

Conditions: Kidney Stone; Ureter Stone; Renal Stone

Summary: the purpose of this research study is to compare how well two treatments work for removing kidney stones. the two study groups include ureteroscopy with long/short pulse lithotripsy to remove kidney stones. both of these options are considered standard of care and are used currently in surgery.

this study will compare two types of laser lithotripsy to see the pulse duration to determine which settings are more effective. this is a randomized control trial with subjects randomized to either long pulse or a short pulse group. those subjects with a single kidney/ureter stone measuring up to 20 mm will be eligible for the study. the procedures will be performed using the standard of care instruments and techniques but the pulse type setting in surgery will be constant. some holmium laser devices provide the option to modulate the pulse duration. a longer laser pulse duration (700 μs or 1500 μs) as compared to a traditional pulse duration (300 μs or 350 μs) has been demonstrated in vitro studies to provide effective stone disintegration while reducing laser fiber tip degradation and stone retropulsion. both the long and the short setting can dust the stone and currently we alternate in each procedure from one setting to the other and it is unclear which setting is more effective. no changes to operative technique will be performed for subjects in the study vs regular patients undergoing the same procedure. all subjects will be seen one week to one month after surgery for stent removal and follow up.

Eligibility criteria:
inclusion criteria: * kidney/ureter single stone between up to 2 cm * age over 18 years * two kidneys exclusion criteria: * solitary kidney * age under 18 * pregnancy

Keywords: basketing dusting holmium laser laser lithotripsy intracorporeal lithotripsy urolithiasis
acute coronary syndome with st elevation in northern lorraine

Conditions: Acute Coronary Syndrome

Summary: lorraine is one of the most affected french region by cardiovascular diseases with a mortality rate for ischemic heart disease higher than the national average in 2010. due to practice change with the new recommandations of the european society of cardiology involving the myocardic revascularization, the investigators wanted to compare the stemi care in 2005-2006, 2010-2011 and 2015 in the chr metz-thionville.

this monocentric study evaluate the impact of the new recommandations of the european society of cardiology in the acute coronary syndrome with st elevation (stemi) care. data is compiled retrospectively from angiographic report and informatic medical record.

Eligibility criteria:
inclusion criteria: * patient with an acute coronary syndrome with st elevation for less than 12 hours * patients with coronarography in a context of cardiorespiratory arrest with unknown cause and acute coronary occlusion exclusion criteria: -
memantine to reduce neurocognitive deficits following unilateral ect for the treatment of a major depression

Conditions: Depressive Disorder, Major

Summary: the purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.

the primary objective of this study is to determine whether the novel nmda antagonist memantine, fda approved for use in moderate to severe alzheimers dementia, may reduce the neurocognitive deficits associated with right unilateral ect treatments in patients receiving ect for a severe and relatively refractory major depressive episode. our hypothesis is that the use of an nmda antagonist would reduce intracellular calcium levels, and glutamatergic stimulation during ect. this reduction in excitatory stimulation during ect would reduce hippocampal and prefrontal neuronal endangerment and dysfunction, thereby reducing cognitive impairment associated with right unilateral ect treatments. we also hypothesize that acth and cortisol levels will correlate with neurocognitive impairment in placebo treated subjects, but not in the memantine treated individuals.

Eligibility criteria:
inclusion criteria:: * meets dsm-iv criteria for major depressive disorder * 18 to 75 years of age and able to provide legal consent * referred to stanford ect service by treating physician for unilateral electroconvulsive therapy with inpatient hospitalization * competed process for consenting to the clinical use of ect according to california state law * females of childbearing potential will be required to use a double-barrier method of contraception, which includes foam and either condom and diaphragm, iud, and/or implant during study.\&#xa; exclusion criteria:- treatment with ect in the 6 months prior to screening * meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening * use of alcohol or illegal drugs within seven days of randomization or during study. patients may be excluded for use during a period greater than 7 days, per study physician's discretion * presence of unstable or untreated cardiovascular disease, hypertension, or endocrine disorder as determined by the investigator * use of antipsychotic, antidepressant, or other prescription medications unless dose is stable for at least 7 days prior to randomization. * use of any investigational treatment within 30 days of randomization * previous allergic reaction to memantine or drugs of similar chemical structure. * women who are pregnant or breastfeeding are not advised to participate in the research study * any neurological disorder or organic brain condition that would confound neurocognitive testing
the empower study: endometriosis diagnosis using microrna

Conditions: Endometriosis

Summary: endometriosis is a complex, heterogeneous disease that may present inconsistently across women. using disease-specific biomarkers and advanced biostatistics, dotlab is developing a biomarker test to confirm the presence of endometriosis.this is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. participants will undergo 2 study visits for collection of blood and saliva and completion of study questionnaires.


Eligibility criteria:
inclusion criteria: 1. participant is willing and able to provide written informed consent. 2. participant is willing and able to provide up to 50 ml of blood via venipuncture and comply with all other study and sample collection procedures. 3. participant is a female aged 18 through 49 years (inclusive). 4. participant is scheduled to undergo: 1. laparotomy or laparoscopy for signs and symptoms of suspected endometriosis. this shall constitute approximately 95% of the participants enrolled. 2. laparotomy, laparoscopy, or other procedures including, but not limited to, tubal ligation, lysis of adhesions, hysterectomy for benign condition, myomectomy, salpingo-oophorectomy, cystectomy, or diagnostic laparoscopy for indications including, but not limited to, infertility or benign gynecological indications (e.g., benign pelvic masses, infertility, abnormal uterine bleeding). this shall constitute approximately 5% of the participants enrolled. exclusion criteria: 1. participant has a history of surgically determined diagnosis of endometriosis (either via visual inspection or histopathology). 2. participant is a female in a pre-menarchal or post-menopausal state (last menstrual period at least 1 year before screening and no other biological or physiological cause can be identified) or has been rendered surgically menopausal (bilateral oophorectomy) for at least 6 months at screening. 3. participant is pregnant. 4. participant has an active malignancy. 5. participant is known to have tested positive for human immunodeficiency virus or hepatitis a, b, or c. 6. participant has an active pelvic infection or other infections contraindicated for surgery. 7. participant has participated (±3 months of study enrollment) in a clinical trial where an investigational drug was or is planned to be administered. 8. participant has any general health or behavioral condition that, in the opinion of the investigator, should exclude the participant from participation.
expression of erythroid differentiation regulator 1 (erdr1) in vitiligo

Conditions: Erythroid Differentiation Regulator 1 (Erdr1) Cytokine

Summary: expression of erythroid differentiation regulator 1 (erdr1) cytokine in vitiligo


Eligibility criteria:
inclusion criteria: * patients with generalized non-segmental vitiligo. * both sexes. * age \>18 years old. * new cases or cases not receiving any medication for at least 3 months ago. exclusion criteria: * segmental or universal vitiligo * autoimmune diseases
does sourdough fermentation improve iron uptake from whole grain rye bread?

Conditions: Iron Bioavailability; Anaemia

Summary: iron deficiency anaemia is a major problem for women worldwide. cereal foods are a major source of iron, but much of this is not bioavailability due to it being bound by the high amounts of phytate present in cereals. destruction of phytate by the phytase enzyme can release iron and increase its bioavailability. in a human cell model of iron uptake, sourdough fermentation, which included activation of phytase, the enzyme that breaks down phyate, led to improved iron bioavailability. this clinical trial will attempt to demonstrate that this concept also works in humans


Eligibility criteria:
inclusion criteria: * healthy women under 50 years old exclusion criteria: * pregnancy or breast feeding * use of mineral or other dietary supplements * use of medical or recreational drugs * donation of blood within the previous 3 months
changing of egyptian population behaviour towards covid 19 outbreak

Conditions: COVID 19

Summary: during the covid-19 pandemic, the egyptian government issued movement restrictions and placed areas into quarantine to reduce the spread of the disease. in addition, individuals were encouraged to adopt personal protective measures, such as social isolation , increasing personal hygiene and wearing protective face masks. information regarding the covid 19 virus and protective measures is found on social media and ministry of health website and a number of the egyptian population are keeping track of them .public awareness play a major rule in reducing the spread of covid 19 so in this study a survey is done to measure the awareness of the egyptian population toward covid 19 , their knowledge and attitude and their adherence to preventive measures.it also measures the change of their behavior during the beginning of the outbreak and after a few months of the outbreak in egypt.

detailed description: the survey will enroll as many individuals of the egyptian population as possible in the survey portion of the study - the number of participates have no limitations, at least 700 participants. the survey will be enrolled in online google form, face to face interview(this will be reduced to encourage social isolation) \& semi-structured telephone interviews if possible. the research procedures: an online survey link will include questions regarding the awareness of the egyptian population , their knowledge , attitudes and behaviour during covid-19 outbreak.and also a comparison of their behaviour among different time periods of the outbreak face to face and semi-structured interviews if possible: for those egyptian citizens who state that they would like to participate in an interview, a random sample will be contacted. inclusion criteria: egyptian population of any age group exclusion criteria: none

Eligibility criteria:
inclusion criteria: egyptian population of different age groups exclusion criteria: none
management of fistula in ano by kshar sutra, para surgical procedure.

Conditions: Fistula in Ano

Summary: background: fistula in ano is one of the most common diseases of the ano rectal region. treatment of fistula in ano has puzzled the medical fraternity due to its complex nature. commonly prevalent surgical treatment for anal fistula, that is "fistulectomy" does not provide successful cure for the disease, post operative complications and recurrences being common. acharya sushruta an ancient indian surgeon has described in his text ' sushruta samhita' about an ancient ayurvedic technique of medicated thread called ksharsutra treatment for bhagandara ( fistula in ano). treatment of anal fistula (bhagandara)and nadi-vrana(sinus) with ksharsutra was practiced by sushruta (1000-600b.c.) . hypothesis: aycharya sushruta advocated kshar sutra therapy in fistula in ano and in various types of fistula.

a 48 years old female patient, came with complaints of painful discharging boil at left side of perianal region with pain. she gave a surgical history of incision and drainage for gluteal abscess done in before four month. on local examination patient had discharging sinus at 3 o' clock position on left side of perianal region. before planning the treatment other aetiologies were ruled out. diagnosis was confirmed by fistulogram, suggestive of high anal fistula with internal opening in the anal canal. under spinal anaesthesia probing was done. internal opening of fistula was confirmed by injecting methylene blue dye through external opening. the track was directed upward in the anal canal without any tributaries. length of the tract was 9cm. then kshar sutra was tied covering the entire underlying track for cutting and healing under all aseptic precaution. the patient was discharged on the next day of procedure. the kshar sutra was changed weekly. to promote healing and to reduce pain and inflammation oral antibiotics, anti-inflammatory medicine were also prescribed. the total period of kshar sutra treatment was 5 month. the kshar sutra was a standard medicated thread smeared with kshar of apamarga (achyranthus aspera), shnuhi (eforbia nerrifolia) which has quality of cutting and haridra(curcuma longa) which is used as a antiseptic. the ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet rediation. the alkalinity of kshar sutra was 9.2ph.

Eligibility criteria:
inclusion criteria: * diagnosis of fistula in ano without tributeries. exclusion criteria: * multiple fistula and associated ano rectal conditions

Keywords: fistula in ano; bhagandar
freedom - first real-life evaluation of enablex done in za overactive bladder patients during a 3 months period

Conditions: Overactive Bladder

Summary: patient perspective on overactive bladder and symptoms experienced after administration of darifenacin


Eligibility criteria:
inclusion criteria: * male and female patients \> 18 years with symptoms of overactive bladder. exclusion criteria: * contraindications for the treatment with darifenacin prolonged-release tablets according to the registered package insert. * pregnancy and lactation. women of childbearing potential have to use an acceptable method of contraception. * concomitant treatment with drugs known to affect mainly the urinary bladder function (e.g. anticholinergics, antispasmodics) at any time during the study. concomitant treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to visit 1.

Keywords: overactive bladder
uremic toxins in the intensive care unit (icu): patients with sepsis

Conditions: Renal Failure; Multi Organ Failure

Summary: study of the kinetics of uremic toxins in the icu patients with acute renal failure, in order to optimize the dialysis dose: patients with sepsis/multi-organ failure. the sampling of blood and dialysate will be done during dialyses with different durations (4, 6 and 8h)


Eligibility criteria:
inclusion criteria: * icu patients with sepsis/multi-organ failure with acute renal failure

Keywords: icu patients with acute renal failure with sepsis/multi-organ failure
pet/ct guided biopsy versus ct guided biopsy in evaluation of suspected lung neoplasms

Conditions: Lung Diseases

Summary: percutaneous ct guided biopsy is a well-established, standard sampling technique for suspected neoplastic lesions located in peripheral region in lung parenchyma. inconclusive results on ct guided biopsy is substantially higher in large lung lesions which are prone to cause peripheral pneumonia, atelectasis and even regional necrosis, which are hard to be distinguished from tumor on ct images. functional imaging guided biopsy like pet/ct guided biopsy identifies areas of highest concentration of neoplastic cells and provides accurate results. only a few studies have been done regarding pet/ct guided biopsy and studies omparing pet/ct guided and ct guided percutaneous transthoracic lung biopsy are very few and this study would be a randomized trial comparing these diagnostic modalities in terms of diagnostic yield, diagnostic accuracy of sample and complications.


Eligibility criteria:
inclusion criteria: * age above 18 years * inr \&lt; 1.2 and platelet counts \&gt; 80,000/mm3 * ct thorax with lung lesion more than 10 mm. * accessible lesions for ct-guided biopsy. exclusion criteria: * participants with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by -inr ≥1.2 and platelet counts ≤ 80,000/mm3 * participants who refuse to provide consent * signs of hypoperfusion like hypotension, cyanosis etc. * presence of hypoxemia with spo2 \< 94 %- measured in a pulse oximeter) * pregnant/lactating female subjects * non-cooperative subjects * lesions that are inaccessible (decision made on pre-biopsy planning) * serum creatinine level more than 2mg/dl.

Keywords: ct guided biopsy pet-ct guided biopsy lung lesions
effects of a ketoacid supplementation in patients with stage iii to iv renal failure

Conditions: Renal Failure

Summary: the aim of the study is to demonstrate that a ketoacid supplement in patients with stage iii to iv chronic renal failure, reduces the excretion of urinary urea nitrogen

patients with an estimated glomerular filtration rate of less than 25 ml/kg/min, not on renal substitution therapy, without important concomitant diseases and aged between 40 and 70 years, will be invited to participate in the study. they will be randomly assigned to a group that will receive receive a supplement of ketoacids (ketosteril) 1 tablet containing 630 mg of ketoacids every 5 kg of body weight and a diet containing 25 to 35 kcal/kg and 0.3 g/protein per day or to a group receiving placebo and a diet containing 25 to 35 kcal/kg and 0.6 g/protein per day. the intervention will last 16 weeks. at baseline and the end of the intervention a blood sample will be obtained to measure creatinine, urea nitrogen and cystatin c. also a spot urine sample will be obtained to measure urea nitrogen and creatinine excretion. the compliance with the dietary prescription and the ketoacid or placebo supplement will be assessed every 2 weeks.

Eligibility criteria:
inclusion criteria: * estimated glomerular filtration rate of less tan 25/ml/min/1.73m2 * not on renal substitution therapy * absence of severe life threatening concomitant diseases exclusion criteria: * malignant or renovascular hypertension * use of systemic steroids or immunosuppressant drugs * alcohol or illicit drug abuse * a body mass index of less tan 18 kg/m2
effects of scapular exercise on patients with scapulocostal syndrome

Conditions: Scapular Pain

Summary: the purpose of this study is to determine the effect of scapular exercise on pain related parameters including pain intensity, 24 hours pain intensity, pressure pain threshold, anxiety and muscle tension in patients with scapulocostal syndrome.


Eligibility criteria:
inclusion criteria: 1. male or female 2. age between 18 - 50 years old 3. the participants have experienced spontaneous scapular pain for longer than 12 weeks (chronic) and that at least one trigger point will be present in the scapular region (serratus posterior superior, rhomboid groups, levator scapulae and trapezius muscles). trigger points will be diagnosed as the presence of focal tenderness in a taut band and with pain recognition (chatchawan et al., 2005; tough et al., 2007). 4. the participants will be able to follow instructions. 5. good communication and cooperation. exclusion criteria: 1. a history of the following diseases or disorders: * rotator cuff disease * cervical radiculopathy * degenerative shoulder joint disease * adhesive capsulitis of shoulder

Keywords: scapular exercises
deep learning enhanced detection of aortic stenosis - the detect-as-diagnostic study

Conditions: Aortic Stenosis

Summary: the detect-as diagnostic study will assess the performance of artificial intelligence (ai) risk predictions to detect aortic stenosis using results from portable electrocardiogram (ecg) and cardiac ultrasound devices.


Eligibility criteria:
inclusion criteria: * age 70 years or older * attending a routine outpatient primary care clinic at one of the three enrollment sites exclusion criteria: * opted out of research studies * non-english speaking * urgent or emergent visits, defined as a visit for an illness or injury that needs attention quickly or is life-threatening * any echocardiogram within 12 months of clinic visit * prior history of moderate or severe as * prior history of aortic valve replacement or repair, including transcatheter and surgical avr with either a bioprosthetic or mechanical valve * presence of implantable cardiac devices, including permanent cardiac pacer, implantable cardioverter-defibrillator, or left ventricular assist device * prior heart transplant * history of dementia * documented life expectancy of \<1 year or current participation in hospice services.

Keywords: aortic stenosis artificial intelligence
a study to assess lbl-007 in combination with toripalimab and axitinib tablets subjects with advanced melanoma

Conditions: Advanced Melanoma

Summary: a phase i clinical study evaluating lbl-007 in the treatment of subjects with advanced solid tumors

this trial is a multi-center, single-arm, open-label, dose-escalation and expansion phase i study of lbl-007 combined with toripalimab and axitinib in the treatment of unresectable or metastatic melanoma. it is divided into study part a and study part b. the safety, tolerability, kinetic characteristics, immunogenicity and preliminary efficacy of the subjects were evaluated. both study part a and study part b are studied in two phases: dose escalation and dose expansion

Eligibility criteria:
inclusion criteria: 1. willingness to provide written informed consent and follow the study treatment plan and visit plan; 2. aged ≥ 18 years at time of signing informed consent, male or female; 3. eastern cooperative oncology group (ecog) performance status score 0 or 1; 4. have life expectancy of at least 12 weeks ; 5. subject with at least one measurable tumor lesion,according to the evaluation standard of solid tumor efficacy (recist 1.1). exclusion criteria: 1. subjects are allergic to lbl-007, pd-1 and similar compounds or any component in the prescription; 2. subjects with active central nervous system metastases (regardless of whether they have received treatment), including symptomatic brain metastases, meningeal metastases, or spinal cord compression, but asymptomatic brain metastases (no progression and/or at least 4 weeks after radiotherapy) no neurological symptoms or signs after surgical resection, and dexamethasone or mannitol treatment is not required); 3. have received major surgery within 4 weeks before the first administration; 4. subjects can not tolerate intravenous administration and have difficulty in venous blood collection (if there is a history of fainting needles and bleeding); 5. women during pregnancy or lactation;